sorafenib has been researched along with Esophageal Squamous Cell Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, YF; Lei, YY; Liu, W; Luo, HH; Yang, HS; Zheng, SY | 1 |
| Jiang, L; Liu, H; Liu, X; Shi, G; Wang, X | 1 |
2 other study(ies) available for sorafenib and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration.
Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gefitinib; Humans; Oxidative Stress; Prognosis; Sorafenib; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2022 |
Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Guanine Nucleotide Exchange Factors; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; T-Lymphoma Invasion and Metastasis-inducing Protein 1; Xenograft Model Antitumor Assays | 2014 |